Comparison of dynamics of wildtype and V94M human UDP-galactose 4-epimerase-A computational perspective on severe epimerase-deficiency galactosemia

Gene

Volumn 526, Issue 2, 2013, Pages 318-324

  Timson, David J ^a   Lindert, Steffen ^b,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Center for Theoretical Biological Physics   (United States)

Author keywords

Molecular dynamics; Type III galactosemia; UDP galactose 4' epimerase

Indexed keywords

HOMODIMER; TYROSINE; URIDINE DIPHOSPHATE GLUCOSE 4 EPIMERASE;

ARTICLE; CATALYSIS; DISEASE SEVERITY; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; GALACTOSEMIA; GENE MUTATION; HYDROGEN BOND; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN UNFOLDING;

DCCM; DYNAMICAL CROSS-CORRELATION MATRIX; GALE; HSGALE; HUMAN UDP-GALACTOSE 4′-EPIMERASE; K(CAT); MD; MOLECULAR DYNAMICS; OMIM #230200; OMIM #230350; OMIM #230400; RMSD; RMSF; ROOT MEAN SQUARE DISTANCE; ROOT MEAN SQUARE FLUCTUATIONS; TURNOVER NUMBER; TYPE I GALACTOSEMIA, GALACTOSE 1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY; TYPE II GALACTOSEMIA; TYPE III GALACTOSEMIA; UDP-GAL; UDP-GALACTOSE 4′-EPIMERASE; UDP-GLC; URIDINE-5′-DIPHOSPHATE GALACTOSE; URIDINE-5′-DIPHOSPHATE GLUCOSE;

CATALYSIS; ESCHERICHIA COLI; GALACTOSEMIAS; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; SUBSTRATE SPECIFICITY; UDPGLUCOSE 4-EPIMERASE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 84880735466     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.05.027     Document Type: Article

References (46)

1. Adcock S.A., McCammon J.A. Molecular dynamics: survey of methods for simulating the activity of proteins. Chem. Rev. 2006, 106:1589-1615.
2. Bang Y.L., Nguyen T.T., Trinh T.T., Kim Y.J., Song J., Song Y.H. Functional analysis of mutations in UDP-galactose-4-epimerase (GALE) associated with galactosemia in Korean patients using mammalian GALE-null cells. FEBS J. 2009, 276:1952-1961.
3. Bosch A.M., Bakker H.D., van Gennip A.H., van Kempen J.V., Wanders R.J., Wijburg F.A. Clinical features of galactokinase deficiency: a review of the literature. J. Inherit. Metab. Dis. 2002, 25:629-634.
4. Brahma A., Banerjee N., Bhattacharyya D. UDP-galactose 4-epimerase from Kluyveromyces fragilis-catalytic sites of the homodimeric enzyme are functional and regulated. FEBS J. 2009, 276:6725-6740.
5. Bulawa C.E., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9629-9634.
6. Case D.A., et al. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26:1668-1688.
7. Chhay J.S., Vargas C.A., McCorvie T.J., Fridovich-Keil J.L., Timson D.J. Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia. J. Inherit. Metab. Dis. 2008, 31:108-116.
8. Daenzer J.M., Sanders R.D., Hang D., Fridovich-Keil J.L. UDP-galactose 4'-epimerase activities toward UDP-Gal and UDP-GalNAc play different roles in the development of Drosophila melanogaster. Plos Genet. 2012, 8:e1002721.
9. Dutta S.K., Ray M., Bhaduri A. Uridine 5'-diphosphate glucose 4-epimerase from Ehrlich ascites-carcinoma cells. J. Biosci. 1985, 9:59-70.
10. Frey P.A. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J. 1996, 10:461-470.
11. Fridovich-Keil J.L. Galactosemia: the good, the bad, and the unknown. J. Cell. Physiol. 2006, 209:701-705.
12. Fridovich-Keil J., Bean L., He M., Schroer R. Epimerase deficiency galactosemia. Epimerase Deficiency Galactosemia 1993, University of Washington, Seattle, WA. R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, M.P. Adam (Eds.).
13. Friedman A.J., Durrant J.D., Pierce L.C., McCorvie T.J., Timson D.J., McCammon J.A. The molecular dynamics of Trypanosoma brucei UDP-galactose 4'-epimerase: a drug target for African sleeping sickness. Chem. Biol. Drug Des. 2012, 80:173-181.
14. Frishman D., Argos P. Knowledge-based protein secondary structure assignment. Proteins 1995, 23:566-579.
15. Hay M., Bhaduri A. UDPGlucose 4-epimerase from Saccharomyces fragilis. Allosteric kinetics with UDP-glucose as substrate. J. Biol. Chem. 1975, 250:4373-4375.
16. Holton J.B., Gillett M.G., MacFaul R., Young R. Galactosaemia: a new severe variant due to uridine diphosphate galactose-4-epimerase deficiency. Arch. Dis. Child. 1981, 56:885-887.
17. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006, 65:712-725.
18. Jacobson M.P., Friesner R.A., Xiang Z., Honig B. On the role of the crystal environment in determining protein side-chain conformations. J. Mol. Biol. 2002, 320:597-608.
19. Jacobson M.P., et al. A hierarchical approach to all-atom protein loop prediction. Proteins 2004, 55:351-367.
20. Kingsley D.M., Kozarsky K.F., Hobbie L., Krieger M. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 1986, 44:749-759.
21. Lai K., Elsas L.J., Wierenga K.J. Galactose toxicity in animals. IUBMB Life 2009, 61:1063-1074.
22. Leloir L.F. The enzymatic transformation of uridine diphosphate glucose into a galactose derivative. Arch. Biochem. Biophys. 1951, 33:186-190.
23. Lindorff-Larsen K., et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010, 78:1950-1958.
24. Maitra U.S., Ankel H. Uridine diphosphate-4-keto-glucose, an intermediate in the uridine diphosphate-galactose-4-epimerase reaction. Proc. Natl. Acad. Sci. U. S. A. 1971, 68:2660-2663.
25. McCorvie T.J., Timson D.J. Structural and molecular biology of type I galactosemia: disease-associated mutations. IUBMB Life 2011, 63:949-954.
26. McCorvie T.J., Timson D.J. The structural and molecular biology of type I galactosemia: enzymology of galactose 1-phosphate uridylyltransferase. IUBMB Life 2011, 63:694-700.
27. McCorvie T.J., Timson D.J. UDP-galactose 4-epimerase (GALE). Handbook of Glycosyltransferases and Related Genes 2013, Springer. N. Taniguchi, K. Honke, M. Fukuda, H. Narimatsu, Y. Yamaguchi, T. Angata (Eds.).
28. McCorvie T.J., Timson D.J. In silico prediction of the effects of mutations in the human UDP-galactose 4'-epimerase gene: towards a predictive framework for type III galactosemia. Gene 2013, 524:95-104.
29. McCorvie T.J., Wasilenko J., Liu Y., Fridovich-Keil J.L., Timson D.J. In vivo and in vitro function of human UDP-galactose 4'-epimerase variants. Biochimie 2011, 93:1747-1754.
30. McCorvie T.J., Liu Y., Frazer A., Gleason T.J., Fridovich-Keil J.L., Timson D.J. Altered cofactor binding affects stability and activity of human UDP-galactose 4'-epimerase: implications for type III galactosemia. Biochim. Biophys. Acta 2012, 1822:1516-1526.
31. Nayar S., Brahma A., Barat B., Bhattacharyya D. UDP-galactose 4-epimerase from Kluyveromyces fragilis: analysis of its hysteretic behavior during catalysis. Biochemistry 2004, 43:10212-10223.
32. Openo K.K., et al. Epimerase-deficiency galactosemia is not a binary condition. Am. J. Hum. Genet. 2006, 78:89-102.
33. Ray M., Bhaduri A. UDPglucose 4-epimerase from Saccharomyces fragilis: asymmetry in allosteric properties leads to unidirectional catalysis. Biochem. Biophys. Res. Commun. 1978, 85:242-248.
34. Ryckaert J.-P., Ciccotti G., Berendsen H.J.C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
35. Santos-Sierra S., et al. Novel pharmacological chaperones that correct phenylketonuria in mice. Hum. Mol. Genet. 2012, 21:1877-1887.
36. Sinko W., Lindert S., McCammon J.A. Accounting for receptor flexibility and enhanced sampling methods in computer-aided drug design. Chem. Biol. Drug Des. 2013, 81:41-49.
37. Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M. Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry 2000, 39:5691-5701.
38. Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M. Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J. Biol. Chem. 2001, 276:20617-20623.
39. Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M. Human UDP-galactose 4-epimerase. Accommodation of UDP-N-acetylglucosamine within the active site. J. Biol. Chem. 2001, 276:15131-15136.
40. Thoden J.B., Henderson J.M., Fridovich-Keil J.L., Holden H.M. Structural analysis of the Y299C mutant of Escherichia coli UDP-galactose 4-epimerase. Teaching an old dog new tricks. J. Biol. Chem. 2002, 277:27528-27534.
41. Timson D.J. Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS J. 2005, 272:6170-6177.
42. Timson D.J. The structural and molecular biology of type III galactosemia. IUBMB Life 2006, 58:83-89.
43. Wallwork S.C. Hydrogen-bond radii. Acta Crystallogr. 1962, 15:758-759.
44. Wohlers T.M., Fridovich-Keil J.L. Studies of the V94M-substituted human UDPgalactose-4-epimerase enzyme associated with generalized epimerase-deficiency galactosaemia. J. Inherit. Metab. Dis. 2000, 23:713-729.
45. Wohlers T.M., Christacos N.C., Harreman M.T., Fridovich-Keil J.L. Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am. J. Hum. Genet. 1999, 64:462-470.
46. Wong S.S., Frey P.A. Fluorescence and nucleotide binding properties of Escherichia coli uridine diphosphate galactose 4-epimerase: support for a model for nonstereospecific action. Biochemistry 1977, 16:298-305.